Vimarsana
Biggest News Aggregation in the World

Pfizer Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Data Today - Breaking & Trending Today

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer - Vimarsana News

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer

Pfizer Inc. today announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the... | June 4, 2022

Healthy Young Girl Suffers Severe Debilitating Effects from the Covid Shot - Vimarsana News

Healthy Young Girl Suffers Severe Debilitating Effects from the Covid Shot

Today on Feedback, I shared the story of Maddie De Garay, a 12-year old girl who volunteered to participate in...

Source: wsau.com
FDA to Hold Advisory Committee Meetings to Discuss Emergency Use Authorization for Booster Doses and COVID-19 Vaccines for Younger Children - Vimarsana News

FDA to Hold Advisory Committee Meetings to Discuss Emergency Use Authorization for Booster Doses and COVID-19 Vaccines for Younger Children

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is announcing two upcoming meetings of its Vaccines and Related Biological Products Advisory...

CNN The Lead With Jake Tapper September 20, 2021 20:03:00 - Vimarsana News

CNN The Lead With Jake Tapper September 20, 2021 20:03:00

Vaccinated. cnn's jason carroll reports, we're still waiting for important details about when shots will go into these arms. >> reporter: it's information parents of younger children have been waiting for. pfizer sharing data that shows its vaccine is safe for 5 to 11-year-olds and elicits a robust antibody response. >> this is going to make a huge difference in the fight against covid-19 and parents, pediatricians and teachers are waiting for this. >> reporter: pfizer plans to submit its data to the fda for emergency use authorization as soon as possible. medical experts say if all goes well,...

XELJANZ® Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis - Vimarsana News

XELJANZ® Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Pfizer Inc. announced today that the European Commission has approved XELJANZ ® for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs . Two formulations were approved, a tablet and a new oral solution . XELJANZ is the first and only ...